# Single Dose Manufacturing Site (Pfizer vs. BIP) And Device (Prefilled Syringe vs. Prefilled Pen) Comparability Study For Bococizumab In Healthy Volunteers

> **NCT02458209** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 470 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** bococizumab PFS:Pfizer
- **BIOLOGICAL:** bococizumab PFS: BIP
- **BIOLOGICAL:** bococizumab PFP

## Key facts

- **NCT ID:** NCT02458209
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 470 (ACTUAL)
- **Last updated:** 2016-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02458209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02458209, "Single Dose Manufacturing Site (Pfizer vs. BIP) And Device (Prefilled Syringe vs. Prefilled Pen) Comparability Study For Bococizumab In Healthy Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02458209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*